The purpose of the study is to identify certain processes following brain injury that may be associated with the risk of developing epilepsy.

The purpose of this study is to evaluate both sporadic (not inherited), and familial (inherited), forms of frontotemporal lobar degeneration (FTLD). Patients include both those who have symptoms of FTLD and those who do not (yet have a family history involving FTLD). This is an observational study, meaning that there is no investigational treatment involved. We will be working with patients for up to a 5 year period to learn more about FTLD using a neurological exam, tests of memory, behavior, and judgement, MRI, and biospecimen collection (blood and/or CSF). This study involves genetic testing of the genes so far identified to be associated with FTLD. The overall goal is to help better understand FTLD, to better understand the genetics of FTLD, and to use the information we learn to guide improved patient care and potential drug development.

This is a study being conducted at many sites across the US to evaluate patients who are older than 50 years old, who have sudden bleeding in the brain (intracerebral hemorrhage) while taking a statin medication. It is unclear if continuing to take a statin medication after this type of injury can increase the risk of another hemorrhage, stroke or cardiac event. This study will assign patients to 1 of 2 groups. One group will continue the statin medication they were taking previously. The other group will discontinue the statin medication. Both groups will be followed for 2 years to see if they have any additional medical events.

The ASPIRE trial aims to study anticoagulant medications in patients who have had an intracerebral hemorrhage (bleeding in the brain) who also have atrial fibrillation (irregular heartbeats). Participants who agree to study participation will receive either Aspirin or Apixaban and followed for 12-36 months to see if they have any other strokes, and follow their general recovery after stroke.

To Assess the Long-Term Safety and Efficacy of ION-682884 in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy